
Mankind Pharma Ltd. (MANKIND): Mankind Pharma Share Price rises 2.62% to Rs 2,307; stock value at Rs 94,531.56 crore
Updated: 17 Sept 2026 • 3:28 pm
Posted by:

Mankind Pharma Share Price is in focus today after the stock rose 2.62% to Rs 2,307 from the previous close of Rs 2,248. The move added Rs 59 to the day’s value and took the market capitalisation to Rs 94,531.56 crore. The stock opened at Rs 2,234.35, touched the same level as the day’s low at Rs 2,234.35, and climbed to Rs 2,307 by the day’s high. On the supplied data, the price event is clear, while a company-specific catalyst is not confirmed. This Mankind Pharma Stock News update therefore focuses on the verified price action, valuation context and healthcare sector comparison. For readers tracking Mankind Pharma Share Price Today, the current move is relevant because it places the stock among the day’s notable risers without requiring any unsupported explanation.
The latest Mankind Pharma Share Price update also shows turnover of Rs 1.23 crore, which is a factual traded-value measure rather than a signal on its own. Univest is tracking the stock against its sector, its peer set and its published financial ratios so that readers can read the move in context. The headline data from today is straightforward: Mankind Pharma Share Price rose, the stock finished at Rs 2,307, and the market capitalisation remained close to the Rs 95,000 crore mark.
Mankind Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,307 |
| Previous Close | Rs 2,248 |
| Today's Move | Rs 59 (+2.62%) |
| Open | Rs 2,234.35 |
| High | Rs 2,307 |
| Low | Rs 2,234.35 |
| Turnover | Rs 1.23 crore |
| Market Capitalisation | Rs 94,531.56 crore |
| Market Cap Category | Large Cap |
Mankind Pharma Ltd. (MANKIND) rose to Rs 2,307 from the previous close of Rs 2,248, a move of Rs 59 or 2.62%. The stock opened at Rs 2,234.35, reached a high of Rs 2,307, recorded a low of Rs 2,234.35.
Mankind Pharma Share Price Today moved higher by Rs 59, or 2.62%, with the session range spanning Rs 2,234.35 to Rs 2,307. The stock closed at the day’s high, compared with the previous close of Rs 2,248. This price rise places Mankind Pharma among the Stocks in News and Top Gainers Today on a price-change basis. The data confirms the share price rise, but it does not establish a company-specific catalyst. For investors following Mankind Pharma Stock Gaining Today, the main facts are the current price, the percentage change, the opening level and the final close. Univest presents the move as a verified Market Update rather than a narrative about cause.
Mankind Pharma Ltd. (MANKIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 94,531.56 crore |
| P/E Ratio | 45.46x |
| P/B Ratio | 5.52x |
| ROE | 12.69% |
| ROCE | 13.24% |
| EPS | Rs 49.45 |
| Book Value Per Share | Rs 407.39 |
| Dividend Yield | 0.04% |
Mankind Pharma Ltd. (MANKIND) fundamental metrics show P/E 45.46x, P/B 5.52x, ROE 12.69%, ROCE 13.24%. These figures provide context only and are not a buy or sell signal.
Mankind Pharma Ltd. has a market capitalisation of Rs 94531.56 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 45.46x, P/B at 5.52x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.69% and ROCE of 13.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 49.45, book value per share of Rs 407.39, dividend yield of 0.04%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.35x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 45.46x |
| Benchmark Median P/E | 31.35x |
| Benchmark Average P/E | 47.81x |
| Benchmark P/E Range | 3.45x to 661.74x |
| Company P/B Ratio | 5.52x |
| Benchmark Median P/B | 2.98x |
| Company ROE | 12.69% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 13.24% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 94,531.56 crore |
| Benchmark Median Market Cap | Rs 735.67 crore |
Mankind Pharma Ltd. (MANKIND) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Mankind Pharma Ltd. (MANKIND) has a P/E ratio of 45.46x, which is above the benchmark median of 31.35x, a difference of +45.01%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Mankind Pharma Ltd. (MANKIND) has a ROE of 12.69%, which is above the benchmark median of 11.78%, a difference of +7.72%. Mankind Pharma Ltd. (MANKIND) has a ROCE of 13.24%, which is below the benchmark median of 13.65%, a difference of -3%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,40,277.97 | 36.77 | 5.14 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,43,965.63 | 83.5 | 13.83 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,84,478.41 | 84.11 | 20.44 | 26.76 | 19.27 |
| Cipla Ltd. | CIPLA | 1,09,949.53 | 32.59 | 3.12 | 11.83 | 16 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,09,625.67 | 24.42 | 4.09 | 19.69 | 21.39 |
Mankind Pharma Ltd. (MANKIND) has a P/E ratio of 45.46x compared with the displayed peer median of 36.77x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.69% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 13.24% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Mankind Pharma Ltd. (MANKIND) has a market capitalisation of Rs 94,531.56 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Mankind Pharma
- The stock rose 2.62% today to Rs 2,307, with a day change of Rs 59.
- Its market capitalisation stands at Rs 94,531.56 crore, which sets the size context for Mankind Pharma Share Price.
- The P/E ratio is 45.46 and the P/B ratio is 5.52, which frames the current valuation discussion.
- ROE is 12.69% and ROCE is 13.24%, giving a profitability and returns snapshot for the stock.
- The company trades in Healthcare and Pharmaceuticals & Drugs, where peer valuation and return comparisons are clearly available.
About Mankind Pharma
Mankind Pharma Ltd. is a Healthcare company operating in Pharmaceuticals & Drugs. The business profile in the supplied data places it within a large listed pharmaceutical universe that includes brands focused on medicines and related healthcare products. For readers tracking Mankind Pharma Stock News and Mankind Pharma Company News, the main company context is that it sits in a sector where valuation, returns and peer comparisons are widely watched.
The company’s published fundamentals show EPS of Rs 49.45, book value of Rs 407.39 and dividend yield of 0.04%, alongside a P/E of 45.46 and P/B of 5.52. That makes the Mankind Pharma Share Price important to assess in both price and financial terms. Univest uses this Company Overview to connect the share price with the company’s reported profitability and sector position, rather than reading the move as a standalone event.
Track Mankind Pharma Share Price on Univest
Use Mankind Pharma Ltd. (MANKIND) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Mankind Pharma Share Price rise today?
Ans. The stock rose 2.62% to Rs 2,307 today, but the supplied data does not confirm a company-specific catalyst. Univest therefore reports the verified move, price range and close without attributing an unsupported reason.
What is Mankind Pharma Share Price Today?
Ans. Mankind Pharma Share Price Today is Rs 2,307. The stock gained Rs 59 from the previous close of Rs 2,248, and the session’s high and close both stood at Rs 2,307.
What is the market capitalisation of Mankind Pharma?
Ans. Mankind Pharma’s market capitalisation is Rs 94,531.56 crore. That places the company well above the sector median and average in the supplied healthcare benchmark, which helps frame the share price in context.
How does Mankind Pharma look on valuation?
Ans. The company’s P/E ratio is 45.46 and its P/B ratio is 5.52. Against the supplied industry set, those levels sit above the sector median and need to be read alongside earnings and returns.
What do EPS, book value and dividend yield show for Mankind Pharma?
Ans. EPS is Rs 49.45, book value is Rs 407.39 and dividend yield is 0.04%. Together, these figures help explain the earnings base, accounting net worth and payout profile behind Mankind Pharma Share Price.
How does Mankind Pharma compare with healthcare peers?
Ans. Mankind Pharma’s market cap is below Sun Pharma, Divi’s Laboratories, Torrent Pharma, Cipla and Zydus Lifesciences. Its P/E and P/B also sit in the middle of the peer set on the supplied numbers.
What do ROE and ROCE indicate for Mankind Pharma?
Ans. ROE is 12.69% and ROCE is 13.24%. These are return measures, not forecasts. They show how the company’s profitability and capital use compare with the same-industry benchmark and selected peers.
Recent Articles

Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
13 November 2026

Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
13 November 2026

Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
13 November 2026

Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
13 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
SC Agrotech Bonus Issue and Stock Split: 4:5 Bonus and 1:10 Split Proposed as the Stock Locks a 5% Upper Circuit at Rs 62.38, Q2 Profit Up 48 Times and What Shareholders Should Check Before the 11 December EGM

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





